Literature DB >> 24089271

[Levels of inflammatory cytokines and plasma cortisol in respiratory syncytial virus bronchiolitis].

Patricia V Díaz1, Aldo A Gaggero, Ricardo A Pinto, Rossana Mamani, Paola A Uasapud, María Rosa Bono.   

Abstract

BACKGROUND: An increased inflammatory innate response may play a role in pathogenesis of respiratory syncytial virus (RSV) infection. AIM: To quantify pro-inflammatory cytokines (IL-6-IL-8, ÍL-2-P and TNF-a) in nasopharyngeal aspirate (NPA) and plasma, and plasma cortisol in previously healthy infants with RSV bronchiolitis. PATIENTS AND METHODS: We studied 49 infants aged less than one year of age with RSV bronchiolitis and 25 healthy controls. Severity was defined using a previously described modified score. We quantified interleukins in NPA and plasma by flow cytometry and plasma cortisol by radioimmunoanalysis.
RESULTS: Among patients with RSV bronchiolitis, 25 were classified as severe and 24 as moderate or mild. Significantly higher levels of IL-6 and IL-8 in NPA and plasma and IL-lfi in NPA were found in children classified as severe, when compared to those with moderate or mild disease and controls. There was a positive correlation between IL-6 and cortisol in plasma (r = 0,55; p < 0,0001) and both were correlated with the severity of the disease.
CONCLUSIONS: RSV bronchiolitis severity was associated with higher levéis of inflammatory interleukins and plasma cortisol.

Entities:  

Mesh:

Substances:

Year:  2013        PMID: 24089271     DOI: 10.4067/S0034-98872013000500004

Source DB:  PubMed          Journal:  Rev Med Chil        ISSN: 0034-9887            Impact factor:   0.553


  6 in total

1.  Does occupational exposure to anesthetic gases lead to increase of pro-inflammatory cytokines?

Authors:  Maurício Martins Chaoul; José Reinaldo C Braz; Lorena Mendes C Lucio; Márjorie A Golim; Leandro Gobbo Braz; Mariana Gobbo Braz
Journal:  Inflamm Res       Date:  2015-09-26       Impact factor: 4.575

2.  Randomized trial to evaluate azithromycin's effects on serum and upper airway IL-8 levels and recurrent wheezing in infants with respiratory syncytial virus bronchiolitis.

Authors:  Avraham Beigelman; Megan Isaacson-Schmid; Geneline Sajol; Jack Baty; Oscar M Rodriguez; Erin Leege; Kevin Lyons; Toni L Schweiger; Jie Zheng; Kenneth B Schechtman; Mario Castro; Leonard B Bacharier
Journal:  J Allergy Clin Immunol       Date:  2014-11-18       Impact factor: 10.793

Review 3.  The Human Immune Response to Respiratory Syncytial Virus Infection.

Authors:  Clark D Russell; Stefan A Unger; Marc Walton; Jürgen Schwarze
Journal:  Clin Microbiol Rev       Date:  2017-04       Impact factor: 26.132

Review 4.  Cytokines in the Respiratory Airway as Biomarkers of Severity and Prognosis for Respiratory Syncytial Virus Infection: An Update.

Authors:  Yaneisi Vázquez; Liliana González; Loreani Noguera; Pablo A González; Claudia A Riedel; Pablo Bertrand; Susan M Bueno
Journal:  Front Immunol       Date:  2019-06-04       Impact factor: 7.561

5.  The azithromycin to prevent wheezing following severe RSV bronchiolitis-II clinical trial: Rationale, study design, methods, and characteristics of study population.

Authors:  Mythili Srinivasan; Leonard B Bacharier; Charles W Goss; Yanjiao Zhou; Jonathan Boomer; Sarah Bram; Dana Burgdorf; Carey-Ann Burnham; Timothy Casper; Mario Castro; Andrea Coverstone; Matthew Haslam; Watcharoot Kanchongkittiphon; Cadence Kuklinski; Qinghua Lian; Kenneth Schechtman; Gregory A Storch; Kelly True; Meghan A Wallace; Huiqing Yin-DeClue; Elizabeth Ahrens; Jinli Wang; Avraham Beigelman
Journal:  Contemp Clin Trials Commun       Date:  2021-06-09

6.  Pro-Inflammatory Cytokines in Nasopharyngeal Aspirate From Hospitalized Children With Respiratory Syncytial Virus Infection With or Without Rhinovirus Bronchiolitis, and Use of the Cytokines as Predictors of Illness Severity.

Authors:  Patricia V Díaz; Gonzalo Valdivia; Aldo A Gaggero; M R Bono; Guillermo Zepeda; Mabel Rivas; Paola Uasapud; Ricardo A Pinto; M Lina Boza; Julia Guerrero
Journal:  Medicine (Baltimore)       Date:  2015-09       Impact factor: 1.817

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.